Abstract
Recent data (RTOG 90–03 and RTOG 99–14) strongly suggest that concomitant boost radiation (AFX-CB) as well as concurrent chemoradiation offer a local control advantage to advanced head and neck cancer patients. RTOG -0129 has sought to address if AFX-CB with concurrent cisplatin is superior to standard radiation plus cisplatin. We report our experience with AFX-CB plus concurrent chemotherapy in treating advanced larynx cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
